Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 390

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California

Open access
Lewnard, Joseph A., Hong, Vennis X., Patel, Manish M., Kahn, Rebecca, Lipsitch, Marc, Tartof, Sara Y.·2022·Nature Medicine

Published version of a preprint

Abstract

Epidemiologic surveillance has revealed decoupling of Coronavirus Disease 2019 (COVID-19) hospitalizations and deaths from case counts after emergence of the Omicron (B.1.1.529) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant globally. However, assessment of the relative severity of Omicron variant infections presents challenges because of differential acquired immune protection against Omicron and prior variants and because longer-term changes have occurred in testing and healthcare practices. Here we show that Omicron variant infections were associated with substantially reduced risk of progression to severe clinical outcomes relative to time-matched Delta (B.1.617.2) variant infections within a large, integrated healthcare system in Southern California. Adjusted hazard ratios (aHRs) for any hospital admission, symptomatic hospital admission, intensive care unit admission, mechanical ventilation and death comparing individuals with Omicron versus Delta variant infection were 0.59 (95% confidence interval: 0.51–0.69), 0.59 (0.51–0.68), 0.50 (0.29–0.87), 0.36 (0.18–0.72) and 0.21 (0.10–0.44), respectively. This reduced severity could not be explained by differential history of prior infection among individuals with Omicron or Delta variant infection and was starkest among individuals not previously vaccinated against COVID-19 (aHR = 0.40 (0.33–0.49) for any hospital admission and 0.14 (0.07–0.28) for death). Infections with the Omicron BA.2 subvariant were not associated with differential risk of severe outcomes in comparison to BA.1/BA.1.1 subvariant infections. Lower risk of severe clinical outcomes among individuals with Omicron variant infection should inform public health response amid establishment of the Omicron variant as the dominant SARS-CoV-2 lineage globally. Comparison of outcomes of SARS-CoV-2 Delta and Omicron infections shows reduced severity of Omicron infections, most notably in unvaccinated individuals, and no differential risk of severe outcomes between subvariants BA.1 and BA.2. The findings highlight the importance of continual assessment of clinical outcomes associated with SARS-CoV-2 variants of concern to inform both medical interventions and healthcare resource management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01887-z

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 36

  1. Taylor, L. Covid-19: Omicron drives weekly record high in global infections. BMJ 376, o66 (2022). · doi:10.1136/bmj.o66
  2. Clarke, K. E. N. et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies—United States, September, 2021-February, 2022. MMWR Morb. Mortal. Wkly Rep 71, 606–608 (2022). · DOI · Paper page
  3. Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. 386, 492–494 (2022). · DOI · Paper page
  4. Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063–1071 (2022). · doi:10.1038/s41591-022-01753-y · Paper page
  5. Tartof, S. Y. et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the Omicron and Delta variants in a large health system in the USA: a test-negative case–control study. Lancet Respir. Med https://doi.org/10.1016/S2213-2600(22)00101-1 (2022). · DOI
  6. Nyberg, T. et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. Lancet 399, 1303–1312 (2022). · DOI · Paper page
  7. Iuliano, A. D. et al. Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods—United States, December 2020–January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 146–152 (2022). · DOI · Paper page
  8. Madhi, S. A. et al. Population immunity and COVID-19 severity with Omicron variant in South Africa. N. Engl. J. Med. 386, 1314–1326 (2022). · DOI · Paper page
  9. Bager, P. et al. Reduced risk of hospitalisation associated with infection with SARS-CoV-2 Omicron variant versus Delta variant in Denmark: an observational cohort study. Lancert Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00154-2 (2022). · DOI · Paper page
  10. Qassim, S. H. et al. Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections. Preprint at https://www.medrxiv.org/content/10.1101/2022.03.02.22271771v1 (2022). · DOI
  11. Wolter, N., Jassat, W., DATCOV-Gen author group, von Gottberg, A. & Cohen, C. Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa. Preprint at https://www.medrxiv.org/content/10.1101/2022.02.17.22271030v1 (2022). · DOI
  12. Lesley, S. et al. Track Omicron’s spread with molecular data. Science 374, 1454–1455 (2021). · DOI
  13. Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022). · doi:10.1056/nejmoa2119451 · Paper page
  14. Stensrud, M. J. & Hernán, M. A. Why test for proportional hazards? JAMA 323, 1401–1402 (2020). · DOI · Paper page
  15. Kürüm, E. et al. Bayesian model averaging with change points to assess the impact of vaccination and public health interventions. Epidemiology 28, 889–897 (2017). · DOI
  16. Strålin, K. et al. Impact of the Alpha VOC on disease severity in SARS-CoV-2-positive adults in Sweden. J. Infect. 84, e3–e5 (2022). · DOI
  17. Garvey, M. I. et al. Observations of SARS-CoV-2 variant of concern B.1.1.7 at the UK’s largest hospital trust. J. Infect. 83, e21–e23 (2021). · doi:10.1016/j.jinf.2021.04.026
  18. Sheikh, A. et al. Severity of Omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00141-4 (2022). · DOI · Paper page
  19. Ulloa, A. C., Buchan, S. A., Daneman, N. & Brown, K. A. Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada. JAMA 327, 1286–1288 (2022). · DOI · Paper page
  20. Peralta-Santos, A. et al. Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2). Preprint at https://www.medrxiv.org/content/10.1101/2022.01.20.22269406v1 (2022). · doi:10.2139/ssrn.4017381
  21. Huynh, D. N. et al. Description and early results of the Kaiser Permanente Southern California COVID-19 home monitoring program. Perm. J. 25, 20.281 (2021). · DOI
  22. Klann, J. G. et al. Distinguishing admissions specifically for COVID-19 from incidental SARS-CoV-2 admissions: a national retrospective EHR study. Preprint at https://www.medrxiv.org/content/10.1101/2022.02.10.22270728v1 (2022). · doi:10.2196/preprints.37931
  23. Sigal, A., Milo, R. & Jassat, W. Estimating disease severity of Omicron and Delta SARS-CoV-2 infections. Nat. Rev. Immunol. 22, 267–269 (2022). · DOI · Paper page
  24. Bhattacharyya, R. P. & Hanage, W. P. Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, e14 (2022). · DOI
  25. Lamba, K. et al. SARS-CoV-2 cumulative incidence and period seroprevalence: results from a statewide population-based serosurvey in California. Open Forum Infect. Dis. 8, ofab379 (2021). · DOI
  26. Carreño, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022). · DOI · Paper page
  27. Griffith, G. J. et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat. Commun. 11, 5749 (2020). · DOI · Paper page
  28. Vandenbroucke, J. P., Broadbent, A. & Pearce, N. Causality and causal inference in epidemiology: the need for a pluralistic approach. Int. J. Epidemiol. 45, 1776–1786 (2016). · DOI · Paper page
  29. Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715–720 (2022). · DOI · Paper page
  30. Abdelnabi, R. et al. The Omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Antivir. Res 198, 105253 (2022). · DOI
  31. Gozzi, N. et al. Preliminary modeling estimates of the relative transmissibility and immune escape of the Omicron SARS-CoV-2 variant of concern in South Africa. Preprint at https://www.medrxiv.org/content/10.1101/2022.01.04.22268721v1 (2022). · DOI
  32. Smith, D. J. et al. COVID-19 mortality and vaccine coverage—Hong Kong. MMWR Morb. Mortal. Wkly Rep. 71, 545–548 (2022). · DOI
  33. Koebnick, C. et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm. J. 16, 37–41 (2012). · DOI · Paper page
  34. León, T. M. et al. COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis—California and New York, May–November 2021. MMWR Morb. Mortal. Wkly Rep. 71, 125–131 (2022). · DOI
  35. Andrejko, K. L. et al. Prevention of COVID-19 by mRNA-based vaccines within the general population of California. Clin. Infect. Dis. 74, 1382–1389 (2021). · DOI
  36. Burnham, K. P. & Anderson, D. R. Multimodel inference: understanding AIC and BIC in model selection. Sociol. Methods Res 33, 261–304 (2004). · DOI · Paper page

Cited by

See all 390

Metadata

Authors
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., & Tartof, S. Y.
Venue
Nature Medicine
Published
2022-06-08
Volume
28
Issue
9
Pages
1933-1943
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4281784908
Cited by
390
References
17
FWCI
42.87
Type
journal article
Language
en
Open access
green
Licence
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01-AI14812701A1)
  • U.S. Department of Health & Human Services | Centers for Disease Control and Prevention (N/A)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. https://app.cochat.ai/papers/10.1038/s41591-022-01887-z
The paper
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., & Tartof, S. Y. (2022). Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nature Medicine. https://doi.org/10.1038/s41591-022-01887-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.